ChemInform Abstract: Synthesis and Pharmacological Approach to Some Spirohydantoins: Relation with the Conformation.

Courtoison, J. C.; Coudert, Pascal; Couquelet, J.; Tronche, P; Jonadet, M; Bastide, P

doi:10.1002/chin.198838194

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A solution of 8 (23.8 mmol) and 4-iodobiphenyl (22.6 mmol) in acetonitrile (80 mL) and DMF (80 mL) was degassed with a stream of nitrogen for 15 min. N , N ′-Dimethylethylenediamine (5.94 mmol), copper(I) iodide (5.94 mmol), and potassium carbonate (71.3 mmol) were added sequentially.…”

Section: Methodsmentioning

confidence: 99%

1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

Váchal

Miao²,

Pierce³

et al. 2012

J. Med. Chem.

View full text Add to dashboard Cite

The discovery of 1,3,8-triazaspiro[4.5]decane-2,4-diones (spirohydantoins) as a structural class of pan-inhibitors of the prolyl hydroxylase (PHD) family of enzymes for the treatment of anemia is described. The initial hit class, spirooxindoles, was identified through affinity selection mass spectrometry (AS-MS) and optimized for PHD2 inhibition and optimal PK/PD profile (short-acting PHDi inhibitors). 1,3,8-Triazaspiro[4.5]decane-2,4-diones (spirohydantoins) were optimized as an advanced lead class derived from the original spiroindole hit. A new set of general conditions for C-N coupling, developed using a high-throughput experimentation (HTE) technique, enabled a full SAR analysis of the spirohydantoins. This rapid and directed SAR exploration has resulted in the first reported examples of hydantoin derivatives with good PK in preclinical species. Potassium channel off-target activity (hERG) was successfully eliminated through the systematic introduction of acidic functionality to the molecular structure. Undesired upregulation of alanine aminotransferese (ALT) liver enzymes was mitigated and a robust on-/off-target margin was achieved. Spirohydantoins represent a class of highly efficacious, short-acting PHD1-3 inhibitors causing a robust erythropoietin (EPO) upregulation in vivo in multiple preclinical species. This profile deems spirohydantoins as attractive short-acting PHDi inhibitors with the potential for treatment of anemia.

show abstract

Section: Methodsmentioning

confidence: 99%

1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

Váchal

Miao²,

Pierce³

et al. 2012

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

ChemInform Abstract: Synthesis and Pharmacological Approach to Some Spirohydantoins: Relation with the Conformation.

Abstract: The spirohydantoins (IV) and (VI) are prepared by Bucherer‐Bergs reaction of the cyclic ketones (I) or (V).

Cited by 1 publication

References 0 publications

1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

Contact Info

Product

Resources

About